References
A novel antidepressant intervention for outpatient psychiatry

Abstract
This article explores the potential of the novel antidepressant dextromethorphan-bupropion in addressing treatment-resistant depression (TRD). Traditional approaches, including selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors, alongside antipsychotic agents, often prove insufficient. Amid a global surge in TRD post-COVID-19, dextromethorphan-bupropion emerges as an effective treatment option for a subset of 52 patients. Results indicated 27 patients experienced improvement within 2 weeks and 43 achieved remission after 2 months of dextromethorphan-bupropion use. While acknowledging limitations, particularly in a medically under-served demographic, this article advocates for the integration of novel antidepressants into TRD management guidelines. Caution must be exercised given the small sample size; however, dextromethorphan-bupropion stands as a promising therapeutic cornerstone offering renewed hope to those navigating the challenging terrain of TRD and prompting broader discussions for future collaborative research.
In the realm of mental health, the persistent challenge of treatment-resistant depression (TRD) has led to a search for innovative solutions (Fava, 2023; Maina et al, 2023; Mancuso et al, 2023; Oliveira-Maia et al, 2024). For those who have tried at least two conventional antidepressants and found little respite in the augmentation of antipsychotic agents, the exploration of novel interventions becomes critical. In this context, dextromethorphan-bupropion emerges as an effective treatment option for those treating TRD (McCarthy et al, 2023).
Traditional therapeutic approaches often prove insufficient in alleviating depressive symptoms in these patients, underscoring the urgent need for a shift towards novel and transformative strategies (Duarte-Díaz et al, 2023; Watson et al, 2023). Dextromethorphan-bupropion, with its distinctive pharmacological profile and mechanism of action, has captured the attention of the psychiatric community as a potential option in the landscape of depression treatment (Khabir et al, 2022).
Register now to continue reading
Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:
What's included
-
Limited access to our clinical or professional articles
-
New content and clinical newsletter updates each month